Mark Weir-Smith

Mark Weir-Smith is a highly experienced professional in quality operations and regulatory affairs, currently holding senior leadership positions at NovaCina and LumaCina since January 2023, and at Bridgewest Perth Pharma since December 2022. Mark also serves as a Medical Assessor for the National Association of Testing Authorities in Australia since 2002, overseeing the accreditation of various testing and manufacturing bodies nationally. Previous roles include leadership positions at Western Diagnostic Pathology, Pfizer, and the Australian Red Cross Blood Service. Mark has contributed to the pharmaceutical industry as Vice President and Board Member of ISPE Australasia and has held senior roles at Sanofi Genzyme and Abbott. Educational qualifications include a Science degree from Curtin University and Business Organizational Leadership from Harvard Business School.